ReviewFrontiers in immunology2026
PANoptosis: a new perspective for targeting programmed cell death after spinal cord injury.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ferroptosis-Pyroptosis Crosstalk in Spinal Cord Injury: Molecular Mechanisms, Emerging Connectors, and Staged Therapeutic Perspectives.Journal of molecular neuroscience : MN · 2026Review
- The ferroptosis-mediated domino effect: metabolic crosstalk from intervertebral disc degeneration to spinal deformity and cord injury: a mini review.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is a devastating condition characterized by a complex cascade of secondary injury following an initial mechanical insult. Among the mechanisms of secondary injury, multiple forms of programmed cell death (PCD)-including apoptosis, necroptosis, and pyroptosis-play key roles in tissue degeneration and loss of function. PANoptosis is a recently proposed concept of cell death that integrates the aforementioned three pro-inflammatory PCD pathways into a single process via a multi-protein complex called the PANoptosome. This review summarizes evidence for the involvement of PANoptosis in SCI pathophysiology and discusses intervention strategies targeting PANoptosis. Targeting PANoptosis offers a novel, holistic approach to mitigating secondary injury in SCI. However, its clinical translation remains challenging and requires further studies to validate efficacy and safety. Elucidating the assembly mechanisms of the PANoptosome and identifying critical regulatory molecules will aid in developing combination therapies and biomarkers to improve neuronal survival and functional recovery in patients with SCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.